Cholesterol is a significant risk factor for non-alcoholic steatohepatitis

被引:31
|
作者
Walenbergh, Sofie M. A. [1 ]
Shiri-Sverdlov, Ronit [1 ]
机构
[1] Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Dept Mol Genet, Maastricht, Netherlands
关键词
cholesterol; inflammation; lipids; liver; non-alcoholic steatohepatitis; FATTY LIVER-DISEASE; HEPATIC GENE-EXPRESSION; DIETARY-CHOLESTEROL; INFLAMMATION; NASH; MICE; ACCUMULATION; STEATOSIS; ATHEROSCLEROSIS; FIBROSIS;
D O I
10.1586/17474124.2015.1092382
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Non-alcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation (steatosis) and inflammation (steatohepatitis). Currently, the exact underlying mechanisms leading to hepatic inflammation remain incompletely understood and therefore therapy options are poor. Analogous to the predominant metabolic risk factor for the metabolic syndrome, NASH patients often display diet-induced dyslipidemia and are therefore also at high risk for cardiovascular disease. Higher lipid levels, in general, are also widely associated with the production of reactive oxygen species during oxidation. However, the exact contribution of the specific type of lipids to hepatic inflammation still remains unclear. In this editorial, we aim to show that cholesterol, in addition to triglycerides and free fatty acids, is an important risk factor in NASH disease pathogenesis. Developing a better understanding of the contribution of lipids underlying NASH pathogenesis is essential for creating effective therapies against this prevalent disease. © 2015 Taylor & Francis.
引用
收藏
页码:1343 / 1346
页数:4
相关论文
共 50 条
  • [31] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [32] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894
  • [33] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [34] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [35] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [36] Metformin in non-alcoholic steatohepatitis
    Urso, R
    Visco-Comandini, U
    LANCET, 2002, 359 (9303): : 355 - 356
  • [37] Diagnosis of non-alcoholic steatohepatitis
    James, OFW
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 34 - 39
  • [38] News on non-alcoholic steatohepatitis
    Roeb, E.
    Nitschmann, S.
    INTERNIST, 2022, 63 (02): : 238 - 242
  • [39] Non-alcoholic steatohepatitis (NASH)
    Michael F. Sorrell
    Sandeep Mukherjee
    Current Treatment Options in Gastroenterology, 1999, 2 (6) : 447 - 450
  • [40] Statins in Non-alcoholic Steatohepatitis
    Torres-Pena, Jose D.
    Martin-Piedra, Laura
    Fuentes-Jimenez, Francisco
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8